Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Boehringer Ingelheim Acquires Nerio Therapeutics, Securing Novel Immune Checkpoint Inhibitor

NextEdge Admin

31 Jul 2024

2 min 42 sec

immune checkpoint inhibitors,Oncology,Genomics,Boehringer Ingelheim

Boehringer Ingelheim is enhancing its immuno-oncology pipeline with the acquisition of Nerio Therapeutics Inc. for up to USD 1.3 billion. This strategic move aims to develop Nerio's innovative preclinical program as a key component of its immuno-oncology portfolio, ultimately improving cancer patient outcomes.

Nerio’s small molecules inhibit protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which function as immune checkpoints. By inhibiting PTPN1/2, these molecules can activate the immune system to target cancer cells.

While current immune checkpoint inhibitors have revolutionized cancer treatment, they do not benefit all patients. Boehringer Ingelheim is dedicated to expanding the reach of immuno-oncology benefits through a comprehensive portfolio of therapies designed to boost the immune system's ability to fight cancer. Nerio’s inhibitors are poised to be a significant addition, potentially effective as single-agent therapies and in combination with other in-house cancer treatments.

Paola Casarosa, Member of the Board of Managing Directors at Boehringer Ingelheim, emphasized the importance of this acquisition: “Securing the rights to Nerio Therapeutics' novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities. This brings us a major step closer to our vision of transforming the lives of people living with cancer.”

Sanford Madigan, partner at Avalon BioVentures and co-founder and CEO of Nerio Therapeutics, added, “We believe Nerio’s small molecule PTPN1/N2 inhibitors have superior drug-like properties and provide a first-in-class opportunity. We are excited to expand Boehringer Ingelheim’s pipeline and commend their commitment to unlocking the full potential of our compounds and their unique approach to fighting cancer.”

This acquisition strengthens Boehringer Ingelheim’s oncology pipeline, positioning it to offer transformative cancer care through smart therapeutic combinations.